Rosuvastatin Calcium

Catalog No.S2169

Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.

Price Stock Quantity  
In DMSO USD 120 In stock
USD 270 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rosuvastatin Calcium Chemical Structure

Rosuvastatin Calcium Chemical Structure
Molecular Weight: 500.57

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Rosuvastatin Calcium is available in the following compound libraries:

Product Information

  • Compare HMG-CoA Reductase Inhibitors
    Compare HMG-CoA Reductase Products
  • Research Area

Product Description

Biological Activity

Description Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.
Targets HMG-CoA reductase [2]
IC50 11 nM
In vitro Rosuvastatin is relatively hydrophilic and is highly selective for hepatic cells; its uptake is mediated by the liver-specific organic anion transporter OATP-C. Rosuvastatin is a high-affinity substrate for OATP-C with apparent association constant of 8.5 μM. [1] Rosuvastatin inhibits cholesterol biosynthesis in rat liver isolated hepatocytes with IC50 of 1.12 nM. Rosuvastatin causes approximately 10 times greater increase of mRNA of LDL receptors than pravastatin. [2] Rosuvastatin (100 μM) decreases the extent of U937 adhesion to TNF-α-stimulated HUVEC. Rosuvastatin inhibits the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels through inhibition of c-Jun N-terminal kinase and nuclear factor-kB in endothelial cells. [3]
In vivo Rosuvastatin is efficient on reducing plasma liquids. Rosuvastatin (3 mg/kg) daily administration for 14 days decreases plasma cholesterol levels by 26% in male beagle dogs with normal cholesterol levels. In cynomolgus monkeys, Rosuvastatin decreases plasma cholesterol levels by 22% [2] Rosuvastatin (20 mg/kg/day) administration for 2 weeks, significantly reduces very low-density lipoproteins (VLDL) in diabetes mellitus rats induced by Streptozocin. [4] Rosuvastatin shows antiatherothromhotic effects in vivo. Rosuvastatin (1.25 mg/kg) significantly inhibits thrombin-induced transmigration of monocvtes across mesenteric venules via inhibition of the endothelial cell surface expression of P-selectin, and increases the basal rate of nitric oxide in aortic segments by 2-fold times. [5] Rosuvastatin (20 mg/kg) inhibits ROS production, normalizes NO-dependent endothelial function and reduces platelet activation in diabetic rats induced by Streptozocin. [6] Rosuvastatin displays cardioprotective effects in vivo. Rosuvastatin (80 mg) is shows to decrease infarct size and improve cardiac mechanical function after ischemia/reperfusion in animal model. The cardioprotective properties of Rosuvastatin may be due to the improvement of coronary blood flow, decrease in resistance of coronary arteries mediated by enhanced eNOS expression, and the subsequent increase in the production of vascular endothelial NO. [7] Rosuvastatin (2.0 mg/kg) attenuates left ventricular hypertrophy produced by transaortic constriction in mice through regulation of Racl protein and NADPH oxidase activities. [8]
Features

Protocol(Only for Reference)

Kinase Assay: [9]

HMG-CoA reductase activity assay The total volume of each assay is 95 μL and the reaction mixture contained 10 μL of the inhibiting compound to be tested and 85 μL of the incubating buffer containing 2 mg/mL liver microsomes, 0.1 M KH2P04, pH 7.2, 5.7 mM dithiothreitol, 10 mM glucose-6-phosphate, 2 U/mL glucose-6-phosphate dehydrogenase, 1 mM NADP, 10 μM miconazole. Control experiments are done without NADPH generating system. All samples are incubated 10 min at 37℃ before addition of 5μL of substrate (unlabelled and 14C-HMG-3-hydroxy-3-methyl glutaryl CoA, final concentration 50 μM, 2.5 nCi/nmole). After 30 min at 37℃, the reaction is stopped by adding 27 μL 1N HCl and 20 μL of unlabelled mevalonolactone (200 μg/assay). The conversion of mevalonic acid to lactone is performed at room temperature for 60 min.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Schneck DW, et al. Clin Pharmacol Ther, 2004, 75(5), 4554-63.

[2] Watanabe M, et al. Bioorg Med Chem, 1997, 5(2), 437-444.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2014-09-13)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02215174 Not yet recruiting Statin Pharmacokinetics Pre and Post Gastric Bypass Surgery University of California, San Francisco|E-DA Hospital December 2014 Phase 1
NCT02082665 Not yet recruiting Cancer GlaxoSmithKline October 2014 Phase 1
NCT02234882 Not yet recruiting HIV/AIDS Bristol-Myers Squibb September 2014 Phase 1
NCT02234492 Not yet recruiting Human Immunodeficiency Virus (HIV)|Cardiovascular Disease (CVD) University of Ottawa Heart Institute|Ontario HIV Treatment Network September 2014 Phase 4
NCT02231931 Not yet recruiting Healthy Boehringer Ingelheim September 2014 Phase 1

view more

Chemical Information

Download Rosuvastatin Calcium SDF
Molecular Weight (MW) 500.57
Formula

C22H28FN3O6S.1/2Ca

CAS No. 147098-20-2
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms ZD4522
Solubility (25°C) * In vitro DMSO 100 mg/mL (199 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethan-3-ylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HMG-CoA Reductase Products

  • Erastin

    Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.

  • DMOG

    DMOG is an antagonist of α-ketoglutarate cofactor and inhibitor for HIF prolyl hydroxylase.

  • AGI-6780

    AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.

  • Fluvastatin Sodium

    Fluvastatin Sodium inhibits HMG-CoA reductase activity with IC50 of 8 nM.

    Features:The order of magnitude of inhibition of each drug on the peroxidation was butylated hydroxytoluene > fluvastatin ≥ probucol ≥ pravastatin.

  • Clinofibrate

    Clinofibrate inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR) with IC50 of 0.47 mM, is a lipid-lowering agent used for controlling high cholesterol and triacylglyceride levels in the blood.

  • Lovastatin

    Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).

  • Atorvastatin Calcium

    Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol.

  • Pravastatin sodium

    Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.

  • Pemetrexed

    Pemetrexed is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively.

  • Tipifarnib

    Tipifarnib (R115777) is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. Phase 3.

    Features:A potent and selective farnesyl protein transferase inhibitor with significant antitumor effects.

Recently Viewed Items

Tags: buy Rosuvastatin Calcium | Rosuvastatin Calcium ic50 | Rosuvastatin Calcium price | Rosuvastatin Calcium cost | Rosuvastatin Calcium solubility dmso | Rosuvastatin Calcium purchase | Rosuvastatin Calcium manufacturer | Rosuvastatin Calcium research buy | Rosuvastatin Calcium order | Rosuvastatin Calcium mouse | Rosuvastatin Calcium chemical structure | Rosuvastatin Calcium mw | Rosuvastatin Calcium molecular weight | Rosuvastatin Calcium datasheet | Rosuvastatin Calcium supplier | Rosuvastatin Calcium in vitro | Rosuvastatin Calcium cell line | Rosuvastatin Calcium concentration | Rosuvastatin Calcium nmr
Contact Us